Search Within

Daniel Vargas Pivato De Almeida

Formats
  1. Journal Article (2)
  2. Meeting Abstract (2)
  3. Review (1)
Groups
  1. Sloan Kettering Institute Postdocs (5)
  2. Department of Medicine (4)
  3. Genitourinary Oncology Service (4)
  4. Solid Tumor Oncology Division (4)
  5. Hematologic Malignancies, Division of (3)
  6. Advanced Practice Providers (1)

More Groups

People
  1. Karen Autio (4)
  2. Daniel Danila (3)
  3. Howard Scher (3)
  4. Susan Slovin (3)
  5. Erica Dayan (2)
  6. Justine Anderson (2)

More People

Years
  1. 2023 (1)
  2. 2020 (4)
Publications
  1. Journal of Clinical Oncology (2)
  2. American Society of Clinical Oncology Educational Book (1)
  3. JAMA Network Open (1)
  4. Journal of Immunotherapy and Precision Oncology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Medical Association (1)
  3. Innovative Healthcare Institute (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations
    Journal Article

    Schmid, S.; Omlin, A.; Higano, C.; Sweeney, C.; Martinez Chanza, N.; Mehra, N.; Kuppen, M. C. P.; Beltran, H.; Condeduca, V.; Vargas Pivato de Almeida, D.; more...
    JAMA Network Open (2020)

    Fulltext@MSK | Save
  • Immune checkpoint blockade for prostate cancer: Niche role or next breakthrough?
    Review

    Vargas P. de Almeida, D.; Fong, L.; Rettig, M. B.; Autio, K. A.
    American Society of Clinical Oncology Educational Book (2020)

    Fulltext@MSK | Save